Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (1051)	1/27/1998 1:21:00 AM
From: Andrew H	Respond to of 2173

Really, I take no pleasure in having called 4. All the biotechs are suffering and it is very depressing. AMLN more than most. I just hope it holds above 4 1/8. Nice bounce today off the lows.

To: D.Right who wrote (1051)	1/27/1998 8:11:00 AM
From: tonyt	Read Replies (1) \| Respond to of 2173

Speaking of mergers, CPQ just bought out Digital. see wsj.com <VGB> --Tony

To: D.Right who wrote (1051)	1/28/1998 1:10:00 AM
From: D.Right	Read Replies (1) \| Respond to of 2173

To make the discussion a little interesting, let's see what negatives have been said about AMLN by critics. 1. Whether pramlintide can get an FDA approval is up in the air. 2. Once approved, pramlintide won't be widely used because is has to be injected and the efficiency is moderate. 3. One product company, too risky. 4. Too far away from 2000, the scheduled NDA time. Well, I don't agree with any of the above point, but I will save my opinion for later. Comments? Anyone? D.Right